4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · Real-Time Price · USD

12.19

+0.54 (4.64%)

At close: Aug 14, 2026, 4:00 PM EDT

12.19

0.00 (0.00%)

After-hours: Aug 14, 2026, 4:20 PM EDT

4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	70.37	60.24	149.34	249.11	52.35	153
Short-Term Investments	290.96	342.41	275.54	39.12	161.2	94.78
Cash & Short-Term Investments	361.33	402.66	424.88	288.23	213.55	247.78
Cash Growth	23.23%	-5.23%	47.41%	34.97%	-13.81%	-10.46%
Accounts Receivable	-	-	-	-	-	0.05
Other Receivables	4.61	-	-	-	-	0.7
Receivables	4.61	-	-	-	-	0.75
Prepaid Expenses	17.01	10.48	10.06	8.36	6.96	7.76
Total Current Assets	382.96	413.13	434.93	296.59	220.51	256.28
Property, Plant & Equipment	28.93	33.01	40.61	31.67	35.35	28.95
Long-Term Investments	69.3	111.38	80.58	10.95	4.91	67.65
Other Long-Term Assets	11.44	9.19	4.26	0.68	1.08	0.6
Total Assets	492.62	566.71	560.38	339.89	261.85	353.49

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.52	11.16	4.39	3.52	3.32	4.76
Accrued Expenses	25.43	26.87	18.87	12.01	8.87	7.74
Current Portion of Leases	5.37	5.59	5.64	3.15	2.66	1.23
Current Unearned Revenue	4.35	0.36	0.26	0.27	0.88	2.6
Total Current Liabilities	47.67	43.99	29.15	18.95	15.73	16.34
Long-Term Leases	14.26	15.82	18.97	11.52	13.47	15.22
Long-Term Unearned Revenue	2.96	0.75	1.06	0.97	1.08	2.49
Other Long-Term Liabilities	0.49	0.5	0.6	0.62	0.23	0.33
Total Liabilities	84.96	61.05	49.78	32.06	30.51	34.38

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	1,266	1,221	1,087	723.14	547.02	526.52
Retained Earnings	-858	-716.3	-576.2	-415.33	-314.49	-207
Comprehensive Income & Other	-0.45	0.73	0.23	0.02	-1.2	-0.42
Total Common Equity	407.66	505.66	510.61	307.83	231.34	319.11
Shareholders' Equity	407.66	505.66	510.61	307.83	231.34	319.11
Total Liabilities & Equity	492.62	566.71	560.38	339.89	261.85	353.49

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	39.22	21.41	24.61	14.67	16.12	16.45
Net Cash (Debt)	391.41	492.62	480.85	284.52	202.34	298.98
Net Cash Growth	-0.65%	2.45%	69.01%	40.61%	-32.32%	8.04%
Net Cash Per Share	6.06	8.50	8.91	7.27	6.25	10.78
Filing Date Shares Outstanding	55.24	51.05	46.3	49.78	33.23	32.24
Total Common Shares Outstanding	55.21	57.61	45.79	43.08	32.63	32.22
Working Capital	335.28	369.15	405.78	277.64	204.78	239.94
Book Value Per Share	7.38	8.78	11.15	7.15	7.09	9.90
Tangible Book Value	407.66	505.66	510.61	307.83	231.34	319.11
Tangible Book Value Per Share	7.38	8.78	11.15	7.15	7.09	9.90
Machinery	-	17.68	17.17	14.61	12.61	7.12
Construction In Progress	-	-	1.18	0.55	0.48	10.07
Leasehold Improvements	-	18.47	17.76	16.9	16.9	2.53

SEC Filings: 10-K · 10-Q